Tivic Health Systems Inc. has named Christina Valauri to its Board of Directors, effective July 1.
Valauri has served as a strategic advisor to the company since April 2023, and brings to the governing body more than 30 years of experience as a seasoned capital markets professional with extensive analytical and management expertise. Valauri has a proven track record as a senior healthcare analyst, U.S. and global head of equity research, senior broker-dealer manager, strategic business consultant, and board director and advisor. As a managing director and senior manager within capital markets, she has successfully developed and executed transformational business strategies in the United States and internationally to drive growth, and provide enhanced operating performance and comprehensive regulatory and supervisory oversight. She has held leadership roles at U.S. and international firms, including as the global director of Research at Cantor Fitzgerald, and senior research management roles at Credit Lyonnais, ING, and Natixis.
“Over the past year, as an advisor to our board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” Tivic Health Board Chair Sheryle Bolton said.
Valauri currently serves as an Entrepreneur in Residence at Weill Cornell Medicine BioVenture eLab, where she applies her skills and experience in life sciences and business. She supports and facilitates the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers and clinicians. Valauri is the founder and CEO of Sagestone Advisory LLC., and also serves as a senior advisor with Hanover International Inc. and Astia.org. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs - Association of American Medical Colleges.
Valauri earned a bachelor of arts degree in biology from Reed College and an MBA from Cornell University.
“I could not be more excited that Christina has agreed to serve on our Board of Directors, particularly as we forge new segments in our bioelectronic portfolio, focused on precision modulation of vagus nerve activity,” Tivic Health CEO Jennifer Ernst stated.
Additionally, independent director Karen Drexler tendered her resignation from the board and the committees thereof, effective Sept. 30, after which she will be continuing with the company as a strategic advisor. Drexler previously served as an advisor to the company from August 2017 through August 2019, when she joined Tivic Health’s board as the company’s first independent director. “Karen was an instrumental force in the early formation of Tivic Health. I deeply appreciate her commitment to Tivic Health’s development for the past eight years and her continued support as a strategic advisor to the company,” Ernst concluded.
Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is a U.S. Food and Drug Administration-approved handheld bioelectronic sinus device.